Melanoma Global Market 2017: Key Players: AB Science, Amgen, Array BioPharma, AVAX Technologies and More
Jan 11, 2018
WiseGuyReports.com adds Exclusive Research on “Melanoma Global Market” reports to its database.
PUNE, INDIA - January 11, 2018 /MarketersMedia/ —
WiseGuyReports published new report, titled “Melanoma - Global Drug Forecast and Market”
Summary
Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure.
Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy, Imlygic (talimogene laherparepvec, Amgen). BRAF and MEK inhibitors were also first introduced to the market in 2011 (Novartis’s Tafinlar [dabrafenib] + Mekinist [trametinib] and Roche’s Zelboraf [vemurafenib] + Cotellic [cobimetinib]). Together, these new MOAs provide renewed hope to improve the treatment outcomes of melanoma patients. These agents will be utilized in early lines of metastatic therapy, and will continue to push the use of chemotherapy to later treatment lines. Although these new treatments have extended the survival of metastatic patients compared with chemotherapy-only regimens, high unmet needs remain for the non-responders to these targeted treatments, especially in BRAF WT patients who are ineligible for BRAF/MEK targeted therapies. A number of promising pipeline products, especially immune checkpoint inhibitors in combinations, will likely change the treatment landscape in the next few years.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2739942-pharmapoint-melanoma-global-drug-forecast-and-market-analysis-to-2026
Late-Stage Pipeline Agents to Have Limited Impact on the Future Melanoma Landscape
GlobalData expects the approval of 10 pipeline agents over the forecast period; however, few of these are expected to have a major impact on the overall melanoma market. Of these pipeline agents, Incyte’s IDO inhibitor epacadostat represents the sales leader with peak-year sales of $383.4M in 2026. Epacadostat will launch in combination with Merck & Co’s Keytruda, with this regimen expected to be the first-to-market anti-PD-1/IDO inhibitor for any cancer indication. Other pipeline agents include Roche’s anti-PD-L1 checkpoint inhibitor, Tecentriq; Novartis’ anti-PD-1 checkpoint inhibitor, PDR-001; Array BioPharma’s BRAF and MEK inhibitors, encorafenib and binimetinib; Polynoma’s melanoma tumor cell line vaccine, seviprotimut-L; AVAX Technologies’ cellular vaccine M-Vax; Philogen’s immunocytokine combination of Daromun; and Provectus’ ablative cytotoxic agent, PV-10.
What Do the Physicians Think?
Interviewed experts reported that a high unmet need remains for BRAF-WT melanoma patients.
“[A main clinical unmet need is that we don’t have] something with a decent response rate in the BRAF wild-type patients.”
5EU Key Opinion Leader
“What is getting lost is that the response rates of these PD-1 agents are still in the range of 30–40% in highly screened and highly selected patients that go on to clinical trials.”
US Key Opinion Leader
Interviewed KOLs call for novel adjuvant therapies to reduce the risk of relapse for resected melanoma and for treatment-related toxicities. Some are enthusiastic about the clinical development of anti-PD-1 immunotherapy in the adjuvant setting.
“We hope and assume that we’re going to have multiple and better adjuvant therapy options [for Stage II and III patients who] become available within the next couple of years, similar to the way that we had multiple new therapies become available for patients with Stage IV disease.”
US Key Opinion Leader
“Oncologists have lost confidence in [the] efficacy of these drugs [interferons]…Also, the oncologists are struggling because we are very concerned about the toxicity of interferons.”
5EU Key Opinion Leader
“I would think that adjuvant therapy is going to be anti-PD-1 in the future.”
US Key Opinion Leader
..CONTINUED
About US
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check
https://www.wiseguyreports.com/conferences
For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check
https://www.wiseguyreports.com/seminars
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: wiseguyreports
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349
For more information, please visit https://www.wiseguyreports.com
Source: MarketersMedia
Release ID: 286000
More News
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.